Eli Lilly (NYSE:LLY) has received diverse opinions from 14 analysts over the past quarter, with 3 bullish, 10 somewhat bullish, and 1 indifferent. The average 12-month price target is $643.21, with a high of $722.00 and a low of $535.00, marking a 4.93% increase from the previous average of $613.00. Analysts from firms like Daiwa Capital, Truist Securities, and Morgan Stanley have maintained or raised their ratings and price targets. Eli Lilly, a drug firm focusing on various therapeutic areas, has shown a revenue growth rate of 36.84% as of September 30, 2023, but has below-average net margin, ROE, and ROA, and a high debt-to-equity ratio of 1.8.